Abstract: A repositionable pocket for an aircraft having a rigid pocket wall pivotally attached to the aircraft sidewall and at least one strap assembly connecting the pocket to the sidewall. The strap assembly has a first end fixable to the sidewall and a second end repositionably fastened to the pocket. The strap is preferably made to be elastic and urges the attached pocket into a closed orientation thereby securing any stowed items between the pocket and the aircraft sidewall. Strap adjustability accommodates different sized objects for stowage.

Abstract: Provided herein are systems for increasing AAV particle production. These systems comprise producer cell lines adapted for the production of AAV particles, as well as methods of producing AAV particles using said producer cell lines. Also provided are AAV particles produced by said production systems, producer cell lines and methods.

Abstract: A method of conversion of imines substituted with —X—R1 into amidines includes reacting a starting material compound including an imine that comprises —X—R1 bound to an imine carbon atom of the imine with a nitrogen-containing reagent to form a product compound including an amidine in place of the imine —X—R1 in the starting material compound. The nitrogen-containing reagent includes a primary amine, a secondary amine, an ammonium salt, or a combination thereof. The variable X is —S—, —O—, or —NH—. The variable R1 is substituted or unsubstituted (C1-C20) hydrocarbyl, wherein R1 is optionally bonded to a solid support. A method of forming a cyclized product includes intramolecularly reacting an amidine with a carbonyl carbon to form the cyclized product including a 4H-imidazolone and/or a derivative thereof.

Abstract: A method of conversion of thioimidates into amidines includes reacting a starting material compound including a thioimidate with a nitrogen-containing reagent to form a product compound including an amidine in place of the thioimidate in the starting material compound. The nitrogen-containing reagent includes a primary amine, a secondary amine, an ammonium salt, or a combination thereof. The thioimidate includes —S—R1, wherein R1 is substituted or unsubstituted (C1-C20)hydrocarbyl. A method of forming a cyclized product includes intramolecularly reacting an amidine with a carbonyl carbon to form the cyclized product including a 4H-imidazolone and/or a derivative thereof.

Abstract: A seat base includes a plurality of linear actuators each having a first end pivotally mounted to a base member and a second end pivotally mounted to a seat member. A controller is adapted for controlling an extension length of each of the plurality of linear actuators in a coordinated manner for adjusting a position of the seat member with six degrees-of-freedom and for damping vibration of the seat member. An active vibration mitigation method for reducing vibrations of an aircraft seat includes receiving vibration data from one or more accelerometers mounted to the aircraft seat and determining a vibration profile based on the vibration data. When vibration mitigation is warranted, control signals for damping vibration are determined and transmitted to a plurality of linear actuators adapted to support the aircraft seat.

Abstract: Techniques for qualifying a candidate supplier are presented. Such techniques may include obtaining a part produced by a candidate supplier and measuring a quantifiable property in each of a plurality of samples to obtain an empirical data set. Such techniques may also include selecting, based on the empirical data set, and fitting to the empirical data set, an appropriate linear mixed model for the quantifiable property. Such techniques may further include computing an acceptance parameter from a mean and standard deviation obtained from the appropriate linear mixed model. The acceptance parameter may include a process capability index or a tolerance interval bound. Such techniques may further include determining that the candidate supplier qualifies based on comparing the acceptance parameter to a threshold.

Abstract: A seat base includes a plurality of linear actuators each having a first end pivotally mounted to a base member and a second end pivotally mounted to a seat member. A controller is adapted for controlling an extension length of each of the plurality of linear actuators in a coordinated manner for adjusting a position of the seat member with six degrees-of-freedom and for damping vibration of the seat member. An active vibration mitigation method for reducing vibrations of an aircraft seat includes receiving vibration data from one or more accelerometers mounted to the aircraft seat and determining a vibration profile based on the vibration data. When vibration mitigation is warranted, control signals for damping vibration are determined and transmitted to a plurality of linear actuators adapted to support the aircraft seat.

Abstract: A seat base includes a plurality of linear actuators each having a first end pivotally mounted to a base member and a second end pivotally mounted to a seat member. A controller is adapted for controlling an extension length of each of the plurality of linear actuators in a coordinated manner for adjusting a position of the seat member with six degrees-of-freedom and for damping vibration of the seat member. An active vibration mitigation method for reducing vibrations of an aircraft seat includes receiving vibration data from one or more accelerometers mounted to the aircraft seat and determining a vibration profile based on the vibration data. When vibration mitigation is warranted, control signals for damping vibration are determined and transmitted to a plurality of linear actuators adapted to support the aircraft seat.

Abstract: Techniques for qualifying a candidate supplier are presented. Such techniques may include obtaining a part produced by a candidate supplier and measuring a quantifiable property in each of a plurality of samples to obtain an empirical data set. Such techniques may also include selecting, based on the empirical data set, and fitting to the empirical data set, an appropriate linear mixed model for the quantifiable property. Such techniques may further include computing an acceptance parameter from a mean and standard deviation obtained from the appropriate linear mixed model. The acceptance parameter may include a process capability index or a tolerance interval bound. Such techniques may further include determining that the candidate supplier qualifies based on comparing the acceptance parameter to a threshold.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: A seat base includes a plurality of linear actuators each having a first end pivotally mounted to a base member and a second end pivotally mounted to a seat member. A controller is adapted for controlling an extension length of each of the plurality of linear actuators in a coordinated manner for adjusting a position of the seat member with six degrees-of-freedom and for damping vibration of the seat member. An active vibration mitigation method for reducing vibrations of an aircraft seat includes receiving vibration data from one or more accelerometers mounted to the aircraft seat and determining a vibration profile based on the vibration data. When vibration mitigation is warranted, control signals for damping vibration are determined and transmitted to a plurality of linear actuators adapted to support the aircraft seat.

Abstract: The present invention features interferon-free therapies for treating Hepatitis C Virus (HCV) genotypes 1b, 2, 3 or 4. In one aspect, the therapies comprises administering Compound 1 (Paritaprevir), Ritonavir, and Compound 2 (Ombitasvir) to a subject infected with HCV genotype 1b or 4, wherein the therapies do not include the administration of any interferon, and the therapies last from 8 to 12 weeks. Preferably, the therapies do not include the administration of any ribavirin.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 16, 12, or 8 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: The present invention features therapies for the treatment of HCV comprising direct-acting antiviral agents. Preferably, the treatment is administered to an HCV-infected patient who has been tested to determine expression levels of microRNAs such as miR-122 or miR-21. In one aspect, the therapies comprise administering one or more direct acting antiviral agents and, optionally ribavirin, to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2, an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.

Abstract: The present invention features therapies for the treatment of HCV comprising direct-acting antiviral agents. Preferably, the treatment is administered to an HCV-infected patient who has been tested to determine methylation status of a CpG island within a promoter region of the IL28B gene. In one aspect, the therapies comprise administering one or more direct acting antiviral agents and, optionally ribavirin, to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2, therapeutic agent 3, an inhibitor of cytochrome P450 (e.g., ritonavir), and/or ribavirin.

Abstract: The present invention features therapies for the treatment of HCV comprising direct-acting antiviral agents. Preferably, the treatment is administered to an HCV-infected patient who has been tested to determine methylation status of a CpG island within a promoter region of the IL28B gene. In one aspect, the therapies comprise administering one or more direct acting antiviral agents and, optionally ribavirin, to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2, therapeutic agent 3, an inhibitor of cytochrome P450 (e.g., ritonavir), and/or ribavirin.

Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection.